Therapeutic area
Dermatology
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
8
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
14
Industry-sponsored
Recruiting Phase 3
13
Industry-sponsored
Recruiting Phase 4 (post-approval)
3
Industry-sponsored
Recent approvals
- Lisraya (Brepocitinib Tosylate) · Priovant Therap NovelPriority reviewOrphanAug 27, 2026
To treat dermatomyositis in adults
- Differin Epiduo Acne Gel (Adapalene and Benzoyl Peroxide) (Adapalene, Benzoyl Peroxide, Adapalene, Benzoyl Peroxide) · Galderma Labs Lp May 22, 2026
- Adquey (Difamilast) · Acrotech Biopharma NovelFeb 12, 2026
To treat mild to moderate atopic dermatitis
- Anzupgo (Delgocitinib) · Leo Pharma As NovelJul 23, 2025
To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response
- Ebglyss (Lebrikizumab-Lbkz) · Eli Lilly and CO NovelSep 13, 2024
To treat moderate-to-severe atopic dermatitis
- Sofdra (Sofpironium Bromide) · Botanix Sb NovelJun 18, 2024
To treat primary axillary hyperhidrosis
- Zevtera (Ceftobiprole Medocaril Sodium) · Istx NovelPriority reviewApr 3, 2024
To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
- Filsuvez (Birch Triterpenes) · Chiesi NovelPriority reviewOrphanDec 18, 2023
To treat wounds associated with dystrophic and junctional epidermolysis bullosa
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
- Istx1
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- SHR-1819Phase 38 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- barzolvolimabCDX-0159Phase 37 trials
Celldex Therapeutics · Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
Largest recruiting Phase 3 trials
- Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)Pivotal-lookingRecruiting
Sagimet Biosciences Inc.Industry
NCT07863193 · 800 participants (planned) · Start Oct 21, 2026 · Primary completion Aug 2027
Drug: Denifanstat · For: Acne Vulgaris
Sites: Bryant, Arkansas; Beverly Hills, California; Fremont, California · 28 sites in all
- Efficacy and Safety of Clascoterone Cream 1% in Facial Acne VulgarisPivotal-lookingRecruiting
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.Industry
NCT06403501 · 692 participants (planned) · Start May 20, 2024 · Primary completion Oct 2026
Drug: Clascoterone; Vehicle cream · For: Acne Vulgaris
Sites: Shanghai, China
- Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne VulgarisPivotal-lookingRecruiting
Eurofarma Laboratorios S.A.Industry
NCT06905210 · 531 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 2027
Drug: Experimental drug (Cyproterone Acetate 2 mg and Ethinyl Estradiol 0.02 mg); Placebo · For: Acne Vulgaris; Acne Vulgaris on the Face
Sites: Salvador, Brazil; Brasília, Brazil; Goiânia, Brazil · 18 sites in all
- Saccharomyces Boulardii CNCM I-745 in Irritable Bowel SyndromePivotal-lookingRecruiting
BiocodexIndustry
NCT07168434 · 406 participants (planned) · Start Oct 22, 2025 · Primary completion Oct 11, 2026
Drug: Saccharomyces Boulardii 250 MG; Placebo 250 mg · For: IBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant); IBS, Mixed Symptoms
Sites: Braga, Portugal; Lisbon, Portugal; Barcelona, Spain · 10 sites in all
- Phase 3 - Evaluation of Veregen® 10% Ointment as New Herbal Topical Treatment for Actinic KeratosisPivotal-lookingRecruiting
Aresus Pharma GmbHIndustry
NCT07137819 · 280 participants (planned) · Start Sep 4, 2024 · Primary completion Mar 2026
Drug: Topical treatment · For: Actinic Keratosis of Face and Scalp
Sites: Strausberg, Germany
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper ExtremitiesPivotal-lookingRecruiting
Sun Pharmaceutical Industries, Inc.Industry
NCT07144852 · 260 participants (planned) · Start Nov 29, 2025 · Primary completion Jan 2027
Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% · For: Actinic Keratosis
Sites: Phoenix, Arizona; Fremont, California; Castle Rock, Colorado · 22 sites in all
- Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and ScalpPivotal-lookingRecruiting
Sun Pharmaceutical Industries, Inc.Industry
NCT07144345 · 160 participants (planned) · Start Nov 19, 2025 · Primary completion Jan 2027
Drug: Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% · For: Actinic Keratosis
Sites: Fremont, California; Aventura, Florida; Rolling Meadows, Illinois · 12 sites in all
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaPivotal-lookingRecruiting
Paradigm TherapeuticsIndustry
NCT07482787 · 80 participants (planned) · Start Jul 21, 2026 · Primary completion May 17, 2027
Drug: SD-101 Dermal Cream (6%); Vehicle (SD-101 0%) · For: Epidermolysis Bullosa (EB)
Sites: Rancho Santa Margarita, California; Redwood City, California; Philadelphia, Pennsylvania · 4 sites in all
- Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT05789056 · 20 participants (planned) · Start Mar 14, 2023 · Primary completion Dec 30, 2026
Drug: QRX003, 4% Lotion · For: Netherton Syndrome
Sites: San Diego, California; Indianapolis, Indiana; Quincy, Massachusetts · 4 sites in all
- Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingRecruiting
Quoin PharmaceuticalsIndustry
NCT07538583 · 16 participants (planned) · Start Mar 19, 2026 · Primary completion Jan 31, 2027
Drug: QRX003 · For: Netherton Syndrome
Sites: Fremont, California; New Haven, Connecticut; Indianapolis, Indiana · 8 sites in all
More: Dermatology news · literature
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.